Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage.
Colorectal Cancer|Non-Small Cell Lung Cancer
DRUG: GDC-1971|DRUG: Osimertinib|DRUG: Cetuximab
Percentage of Participants with Adverse Events (AEs) Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0, Up to approximately 41 months|Number of Participants with Dose-Limiting Toxicities (DLTs), Day 1 through Day 28 of Cycle 1 (1cycle= 28 days)
Plasma Concentration of GDC-1971, Up to approximately 41 months|Plasma Concentration of Osimertinib, Up to approximately 41 months|Objective Response Rate (ORR) as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)., Up to approximately 41 months|Duration of Response (DOR) as Determined by Investigator According to RECIST v1.1, Up to approximately 41 months|Progression-Free Survival (PFS) After Enrollment as Determined by Investigator According to RECIST v1.1, Up to approximately 41 months
The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage.